In Europe, there are over 80 million people at risk to be infected. HIV is regularly tested on the spot, whereas Viral Hepatitis testing is usually not included, as most syndromic approaches are limited to laboratory assays and not conducted at the Point-of-Care. Consequently, HIV cases are well-diagnosed, but awareness of viral Hepatitis status remains low, with less than 20% of those infected being aware of their status.
This highlights the need for a combined screening approach at the Point-of-Care to better manage the epidemics and link key populations to care.
In response to this demand, we have developped the MagIA IBC test. This specialized test is designed for the detection of active infections and specifically screens for anti-HIV, anti-HCV, and HBsAg in capillary blood samples.